http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Jun 2026 13:29:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/Press+Releases/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/no..oslo" idsrc="xmltag.org" >OSLO, Norway</location></span>, <span class="legendSpanClass"><chron>June 8, 2026</chron></span> /PRNewswire/ -- <b><span value="Oslo:PHO" idsrc="xmltag.org" >Photocure ASA</span> </b>(OSE: PHO)<b>, the <span>Bladder Cancer Company</span>, and Artera, a leading precision medicine company, announce launch of a joint research initiative. The collaboration encompasses <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure's</span> blue light cystoscopy (BLC</b><b>^®</b><b>) registry in bladder cancer and the ArteraAI Bladder Test, an AI-powered digital pathology test currently in development for patients with bladder cancer.</b></p> <p>As healthcare systems increasingly embrace precision medicine, the demand for advanced precision diagnostics in uro-oncology continues to grow. <span value="Oslo:PHO" idsrc="xmltag.org" >Photocure</span>, already recognized for its proven leadership in bladder http://www.streetinsider.com/PRNewswire/Photocure+and+Artera+to+partner+on+digital+pathology+AI+test+evaluation+for+Bladder+Cancer/26616473.html Mon, 08 Jun 2026 13:29:00 -0400 A.22847412 O.00564781 O.03960636 OSAKA PHO PHO http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html <p>Photocure ASA (OSE: PHO) announced the completion of its acquisition of Vesica Health Inc., a U.S. precision diagnostics company, for $30.5 million in cash and stock. The transaction adds AssureMDx, a urine-based molecular test for early bladder cancer detection, to Photocure's diagnostic portfolio.</p> <p>The deal structure includes $13.75 million due at closing, comprised of $11 million in cash and $2.75 million in Photocure equity. An additional $13.75 million depends on future Medicare reimbursement milestones through December 2029, split between $5.5 million cash and $8.25 million in equity.</p> <p>AssureMDx integrates six epigenetic and somatic biomarkers to help identify hematuria patients at increased risk http://www.streetinsider.com/Mergers+and+Acquisitions/Photocure+acquires+Vesica+Health+for+%2430.5+million+in+bladder+cancer+deal/26604284.html Thu, 04 Jun 2026 11:47:29 -0400 A.06822034 A.21839488 A.24394000 A.28005717 A.30142833 A.50200979 O.00003102 O.00049141 O.00564781 O.00871851 O.20020231 O.20026344 OSAKA PHO PHO.OL